

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT6295957

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
THOMAS BRIMERT	06/07/2017
RICHARD JOHNSSON	06/07/2017
HAKON LEFFLER	06/10/2017
ULF NILSSON	06/07/2017
FREDRIK ZETTERBERG	06/07/2017

RECEIVING PARTY DATA

Name:	GALECTO BIOTECH AB
Street Address:	COBIS OLE MAALØES VEJ 3
City:	COPENHAGEN
State/Country:	DENMARK
Postal Code:	2200

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	17018713

CORRESPONDENCE DATA

Fax Number: (703)991-7071

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: patent@MAIERANDMAIER.COM

Correspondent Name: MAIER & MAIER, PLLC

Address Line 1: 345 SOUTH PATRICK STREET

Address Line 4: ALEXANDRIA, VIRGINIA 22314

ATTORNEY DOCKET NUMBER:	09390002COB
NAME OF SUBMITTER:	TIMOTHY J. MAIER
SIGNATURE:	/Timothy J. Maier/
DATE SIGNED:	09/14/2020

Total Attachments: 5

source=Assignment#page1.tif

source=Assignment#page2.tif

PATENT

REEL: 053767 FRAME: 0118

source=Assignment#page3.tif
source=Assignment#page4.tif
source=Assignment#page5.tif

DECLARATION AND ASSIGNMENT

Title of Invention: ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS

DECLARATION

As a below named inventor, I hereby declare that:
This declaration is directed to:



The attached application, or



United States application or PCT international application number....., filed
on

The above-identified application was made or authorized to be made by me. I believe I am the original inventor or an original joint inventor of a claimed invention in the application. I have reviewed and understand the contents of the above-identified application, including the claims, and any claim amendments made in the application. I acknowledge the duty to disclose all information which is material to patentability as defined in 37 CFR 1.56.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 USC 1001 by fine or imprisonment of not more than five (5) years, or both.

ASSIGNMENT

WHEREAS, I, Thomas BRIMERT, whose post office address is Hammakullavagen 13, 273 64 Biskorp (SE), hereinafter referred to as ASSIGNEE, am the owner of useful improvements in ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS (hereinafter referred to as the INVENTION) for which the above application for United States Letters Patent was filed on 14-JUN-2017 Serial No. 15535829 or established by PCT International Patent Application No.: filed designating the United States of America;

WHEREAS, GALECTO BIOTECH AB, whose post office address is Cabis Ole Maaløe Vej 3, 2200 Copenhagen (DK), hereinafter referred to as ASSIGNEE, is desirous of acquiring the entire right, title and interest in and to the same in the United States;

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, I, ASSIGNEE, by these presents do sell, assign and transfer unto said ASSIGNEE, the entire right, title, and interest in and to said INVENTION and application throughout the United States of America, including any and all Letters Patent granted on any division, continuation, continuation-in-part and reissue of said application.

ALSO, ASSIGNEE hereby agrees to execute any documents that legally may be required in connection with the filing, prosecution and maintenance of said application or any other patent application(s) in the United States for said INVENTION, including additional documents that may be required to affirm the rights of ASSIGNEE in and to said INVENTION, all without further consideration. ASSIGNEE also agrees, without further consideration and at ASSIGNEE's expense, to identify and communicate to ASSIGNEE at ASSIGNEE's request documents and information concerning the INVENTION that are within ASSIGNEE's possession or control, and to provide further assurances and testimony on behalf of ASSIGNEE that lawfully may be required of ASSIGNEE in respect of the prosecution, maintenance and defense of any patent application or patent encompassed within the terms of this instrument. ASSIGNEE's obligations under this instrument shall extend to ASSIGNEE's heirs, executors, administrators and other legal representatives.


ALSO, ASSIGNEE hereby authorizes and requests the Director of the U.S. Patent and Trademark Office to issue any and all Letters Patent referred to above to ASSIGNEE, as the Assignee of the entire right, title and interest in and to the same, for ASSIGNEE's sole use and benefit; and for the use and benefit of ASSIGNEE's legal representatives and successors, to the full end of the term for which such Letters Patent may be granted, as fully and entirely as the same would have been held by ASSIGNEE had this assignment and sale not been made.

ASSIGNEE authorizes any member of the firm of Maier & Maier, PLLC to insert or complete any information in this document needed to effect its recordal in the U.S. Patent and Trademark Office.

Legal Name of Inventor: Thomas BRIMERT

A handwritten signature in black ink, appearing to read "Thomas Brimert".

Inventor's Signature

A handwritten date in black ink, reading "2017-06-07".

Date

DECLARATION AND ASSIGNMENT

Title of Invention: ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS

DECLARATION

As a below named inventor, I hereby declare that:
This declaration is directed to:

- The attached application, or
 United States application or PCT international application number filed
on

The above-identified application was made or authorized to be made by me. I believe I am the original inventor or an original joint inventor of a claimed invention in the application. I have reviewed and understood the contents of the above-identified application, including the claims, and any claim amendments made in the application. I acknowledge the duty to disclose all information which is material to patentability as defined in 37 CFR 1.56.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 USC 1001 by fine or imprisonment of not more than five (5) years, or both.

ASSIGNMENT

WHEREAS, I, Richard JOHNSSON, whose post office address is Smedgatan 2b, 222 37 Lund (SE), hereinafter referred to as ASSIGNEE, am the owner of useful improvements in ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS (hereinafter referred to as the INVENTION) for which the above application for United States Letters Patent was filed on 14-JUN-2017 Serial No. 15535829

established by PCT International Patent Application No. filed
designating the United States of America,

WHEREAS, GALECTOBIOOTECH AB, whose post office address is Cabis Gle Maslæs Vej 3, 2200 Copenhagen (DK), hereinafter referred to as ASSORER, is desirous of acquiring the entire right, title and interest in and to the same in the United States;


NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, I, ASSIGNEE, by these presents do sell, assign and transfer unto said ASSORER, the entire right, title, and interest in and to said INVENTION and application throughout the United States of America, including any and all Letters Patent granted on any division, continuation, continuation-in-part and reissue of said application.

ALSO, ASSIGNEE hereby agrees to execute any documents that legally may be required in connection with the filing, prosecution and maintenance of said application or any other patent application(s) in the United States for said INVENTION, including additional documents that may be required to affirm the rights of ASSIGNEE in and to said INVENTION, all without further consideration. ASSIGNEE also agrees, without further consideration and at ASSIGNEE's expense, to identify and communicate to ASSORER at ASSORER's request documents and information concerning the INVENTION that are within ASSIGNEE's possession or control, and to provide further assurances and testimony on behalf of ASSIGNEE that lawfully may be required of ASSORER in respect of the prosecution, maintenance and defense of any patent application or patent encompassed within the terms of this instrument. ASSIGNEE's obligations under this instrument shall extend to ASSIGNEE's heirs, executors, administrators and other legal representatives.

ALSO, ASSORER hereby authorizes and requests the Director of the U.S. Patent and Trademark Office to issue any and all Letters Patent referred to above to ASSORER, as the ASSIGNEE of the entire right, title and interest in and to the same, for ASSORER's sole use and benefit, and for the use and behoof of ASSORER's legal representatives and successors, to the full end of the term for which such Letters Patent may be granted, as fully and entirely as the same would have been held by ASSIGNEE had this assignment and sale not been made.

ASSIGNEE authorizes any member of the firm of Maier & Maier, PLLC to insert or complete any information in this document needed to effect its recordal in the U.S. Patent and Trademark Office.

Legal Name of Inventor: Richard JOHNSSON


X
Inventor's Signature

x 1st JUN 2017
Date

DECLARATION AND ASSIGNMENTTitle of Invention: ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS**DECLARATION**

As a below named inventor, I hereby declare that:

This declaration is directed to:

- The attached application, or
 United States application or PCT international application number _____, filed
 on _____

The above-identified application was made or authorized to be made by me. I believe I am the original inventor or an original joint inventor of a claimed invention in the application. I have reviewed and understood the contents of the above-identified application, including the claims, and any claim amendments made in the application. I acknowledge the duty to disclose all information which is material to patentability as defined in 37 CFR 1.56.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 USC 1001 by fine or imprisonment of not more than five (5) years, or both.

ASSIGNMENT

WHEREAS, I, Hakan LEFFLER, whose post office address is Svenegatan 7B, 222 24 Lund (SE), hereinafter referred to as ASSIGNEE, am the owner of useful improvements in ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS (hereinafter referred to as the INVENTION) for which the above application for United States Letters Patent was filed on 14-JUN-2017 Serial No. 15535829; or established by PCT International Patent Application No. _____ filed _____ designating the United States of America;

WHEREAS, GALECTO BIOTECHLAB, whose post office address is Colis Ole Maingers Vej 3, 2200 Copenhagen (DK), hereinafter referred to as ASSIGNEE, is desirous of acquiring the entire right, title and interest in and to the same in the United States;

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, I, ASSIGNEE, by these presents do sell, assign and transfer unto said ASSIGNEE, the entire right, title, and interest in and to said INVENTION and application throughout the United States of America, including any and all Letters Patent granted on any division, continuation, continuation-in-part and reissue of said application.

ALSO, ASSIGNEE hereby agrees to execute any documents that legally may be required in connection with the filing, prosecution and maintenance of said application or any other patent application(s) in the United States for said INVENTION, including additional documents that may be required to affirm the rights of ASSIGNEE in and to said INVENTION, all without further consideration. ASSIGNEE also agrees, without further consideration and at ASSIGNEE's expense, to identify and communicate to ASSIGNEE at ASSIGNEE's request documents and information concerning the INVENTION that are within ASSIGNEE's possession or control, and to provide further assurances and testimony on behalf of ASSIGNEE that lawfully may be required of ASSIGNEE in respect of the prosecution, maintenance and defense of any patent application or patent encompassed within the terms of this instrument. ASSIGNEE's obligations under this instrument shall extend to ASSIGNEE's heirs, executors, administrators and other legal representatives.

ALSO, ASSIGNEE hereby authorizes and requests the Director of the U.S. Patent and Trademark Office to issue any and all Letters Patent referred to above to ASSIGNEE, as the ASSIGNEE of the entire right, title and interest in and to the same, for ASSIGNEE's sole use and behoof, and for the use and behoof of ASSIGNEE's legal representatives and successors, to the full end of the term for which such Letters Patent may be granted, as fully and entirely as the same would have been held by ASSIGNEE had this assignment and sale not been made.

ASSIGNEE authorizes any member of the firm of Maier & Maier, PLLC to insert or complete any information in this document needed to effect its recordal in the U.S. Patent and Trademark Office.

Legal Name of Inventor: Hakan LEFFLER

X Hakan Leffler
 Inventor's Signature

June 10, 2017
 X _____
 Date

DECLARATION AND ASSIGNMENT

Title of Invention: ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS

DECLARATION

As a below named inventor, I hereby declare that:

This declaration is directed to:

- The attached application, or
 United States application or PCT international application number _____, filed
 on _____.

The above-identified application was made or authorized to be made by me. I believe I am the original inventor or an original joint inventor of a claimed invention in the application. I have reviewed and understood the contents of the above-identified application, including the claims, and any claim amendments made in the application. I acknowledge the duty to disclose all information which is material to patentability as defined in 37 CFR 1.56.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 USC 1001 by fine or imprisonment of not more than five (5) years, or both.

ASSIGNMENT

WHEREAS, I, Ulf Nilsson, whose post office address is Smedsbovägen 10, 225 94 Lund (SE), hereinafter referred to as **ASSIGNOR**, am the owner of useful improvements in ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS (hereinafter referred to as the **INVENTION**) for which the above application for United States Letters Patent was filed on: 14-JUN-2017 Serial No.: 15535829; or established by PCT International Patent Application No.: _____ filed: _____ designating the United States of America;


WHEREAS, GALECTO BIOTECH AB, whose post office address is Cobis Ole Maalgås Vej 3, 2200 Copenhagen (DK), hereinafter referred to as **ASSIGNEE**, is desirous of acquiring the entire right, title and interest in and to the same in the United States;

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, I, **ASSIGNOR**, by these presents do sell, assign and transfer unto said **ASSIGNEE**, the entire right, title, and interest in and to said **INVENTION** and application throughout the United States of America, including any and all Letters Patent granted on any division, continuation, continuation-in-part and reissue of said application.

ALSO, **ASSIGNOR** hereby agrees to execute any documents that legally may be required in connection with the filing, prosecution and maintenance of said application or any other patent application(s) in the United States for said **INVENTION**, including additional documents that may be required to affirm the rights of **ASSIGNEE** in and to said **INVENTION**, all without further consideration. **ASSIGNOR** also agrees, without further consideration and at **ASSIGNEE**'s expense, to identify and communicate to **ASSIGNEE** at **ASSIGNEE**'s request documents and information concerning the **INVENTION** that are within **ASSIGNOR**'s possession or control, and to provide further assurances and testimony on behalf of **ASSIGNEE** that lawfully may be required of **ASSIGNOR** in respect of the prosecution, maintenance and defense of any patent application or patent encompassed within the terms of this instrument. **ASSIGNOR**'s obligations under this instrument shall extend to **ASSIGNOR**'s heirs, executors, administrators and other legal representatives.

ALSO, **ASSIGNOR** hereby authorizes and requests the Director of the U.S. Patent and Trademark Office to issue any and all Letters Patent referred to above to **ASSIGNEE**, as the **ASSIGNEE** of the entire right, title and interest in and to the same, for **ASSIGNEE**'s sole use and behoof; and for the use and behoof of **ASSIGNEE**'s legal representatives and successors, to the full end of the term for which such Letters Patent may be granted, as fully and entirely as the same would have been held by **ASSIGNOR** had this assignment and sale not been made.

ASSIGNOR authorizes any member of the firm of Maier & Maier, PLLC to insert or complete any information in this document needed to effect its recordal in the U.S. Patent and Trademark Office.

Legal Name of Inventor: Ulf Nilsson

Inventor's Signature

X June 7, 2017

Date

DECLARATION AND ASSIGNMENT

Title of Invention: ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS

DECLARATION

As a below-named inventor, I hereby declare that:
This declaration is directed to:



The attached application, or



United States application or PCT international application number filed

on

The above-identified application was made or authorized to be made by me. I believe I am the original inventor or an original joint inventor of a claimed invention in the application. I have reviewed and understood the contents of the above-identified application, including the claims, and any claim amendments made in the application. I acknowledge the duty to disclose all information which is material to patentability as defined in 37 CFR 1.56.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 USC 1001 by fine or imprisonment of not more than five (5) years, or both.

ASSIGNMENT

WHEREAS, I, **Fredrik ZETTERBERG**, whose post office address is **Ringsvej 8, 2200 København (DK)**, hereinafter referred to as **ASSIGNEE**, am the owner of useful improvements in **ALPHA-D-GALACTOSIDE INHIBITORS OF GALECTINS** (hereinafter referred to as the **INVENTION**) for which the above application for United States Letters Patent was
14-JUN-2017 Serial No. 15535829 or
established by PCT International Patent Application No. filed.....
designating the United States of America;

WHEREAS, **GALECTO BIOTECH A/S**, whose post office address is **Cobis Ole Maassens Vej 3, 2222 Copenhagen (DK)**, hereinafter referred to as **ASSIGNEE**, is desirous of acquiring the entire right, title and interest in and to the same in the United States;

NOW, THEREFORE, for good and valuable consideration, receipt of which is hereby acknowledged, I, **ASSIGNEE**, by these presents do sell, assign and transfer unto said **ASSIGNEE**, the entire right, title, and interest in and to said **INVENTION** and application throughout the United States of America, including any and all Letters Patent granted on any division, continuation, continuation-in-part and reissue of said application.

ALSO, **ASSIGNEE** hereby agrees to execute any documents that legally may be required in connection with the filing, prosecution and maintenance of said application or any other patent application(s) in the United States for said **INVENTION**, including additional documents that may be required to affirm the rights of **ASSIGNEE** in and to said **INVENTION**, all without further consideration. **ASSIGNEE** also agrees, without further consideration and at **ASSIGNEE**'s expense, to identify and communicate to **ASSIGNEE** all **ASSIGNEE**'s request documents and information concerning the **INVENTION** that are within **ASSIGNEE**'s possession or control, and to provide further assurances and testimony on behalf of **ASSIGNEE** that lawfully may be required of **ASSIGNEE** in respect of the prosecution, maintenance and defence of any patent application or patent encompassed within the terms of this instrument. **ASSIGNEE**'s obligations under this instrument shall extend to **ASSIGNEE**'s heirs, executors, administrators and other legal representatives.

ALSO, **ASSIGNEE** hereby authorizes and requests the Director of the U.S. Patent and Trademark Office to issue any and all Letters Patent referred to above to **ASSIGNEE**, as the Assignee of the entire right, title and interest in and to the same, for **ASSIGNEE**'s sole use and benefit, and for the use and benefit of **ASSIGNEE**'s legal representatives and successors, to the full end of the term for which such Letters Patent may be granted, as fully and entirely as the same would have been held by **ASSIGNEE** had this assignment and sale not been made.

ASSIGNEE authorizes any member of the firm of **Maier & Maier, PLLC** to insert or complete any information in this document needed to effect its recordation in the U.S. Patent and Trademark Office.

Legal Name of Inventor: **Fredrik ZETTERBERG**



Inventor's Signature

2070602

Date